Leukemia

A new combination of Blincyto and Iclusig provided improved results and stronger responses for patients with Philadelphia chromosome-positive ALL compared with traditional chemotherapy.

Among fit patients with acute myeloid leukemia, azacitidine plus Venclexta was shown to be superior to intensive chemotherapy.

Race has been identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

Venclexta regimens showed comparable progression-free survival versus continuous Imbruvica.

For pediatric and young adult patients with B-cell acute lymphoblastic leukemia, removal of total body irradiation did not compromise efficacy.

Among children receiving chemotherapy for acute lymphoblastic leukemia, 30% of their families developed catastrophic financial toxicity.

Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of.

I experienced acute myeloid leukemia twice. Had it not been for follow up appointments I would not be here.

Dr. Jorge E. Cortes discussed the evolution of chronic myeloid leukemia treatment and emerging strategies aimed at improving outcomes and quality of life.

The FDA has approved Revuforj for relapsed or refractory acute myeloid leukemia with an NPM1 mutation.

The author and advocate, facing leukemia for the third time in 15 years, sat down for an interview with CURE.

Leukemia is a blood cancer that disrupts normal cell production, leading to infection risk, anemia and bleeding, and requiring tailored treatments.

The changing seasons offer a profound metaphor for the circle of life, an idea that resonates deeply with me.

In observation of Leukemia Awareness Month in September, CURE spoke with an expert about basics of the disease.

Facing a cancer diagnosis was terrifying, but determination, lifestyle changes, and a strong support system helped me fight and find hope.

Facing leukemia and uncertainty, I leaned on love and resolve to keep living day by day, despite fear and an unknown future ahead.

I’m in remission from small lymphocytic lymphoma and off treatment, savoring this break while learning to live with the uncertainty that still lingers.

I celebrated five years since my bone marrow transplant with a surprise video from my donor, a beautiful reminder of the life she helped me keep.

The FDA has granted priority review to an application for Revuforj for the treatment of relapsed or refractory mutant NPM1 acute myeloid leukemia.

I’ve lived with large granular lymphocytic leukemia for 16 years and have learned to spend my energy wisely, embrace palliative care and choose joy over anger.

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm working to balance both.

The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.

Nutrition is a challenge for many patients with cancer.